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Globalization and Innovation in the Indian Pharmaceutical Industry 
 
Bishwanjit Loitongbam
 
Abstract:  The changing global environment brings about new opportunities and new 
markets for domestic firms in developing countries. We examine the impacts of globalization 
and IPR protection on the innovation in the Indian pharmaceutical industry, using the firm-
level panel data. This paper finds that there is a positive and highly significant level of 
foreign ownership effect on R&D activities. This indicates that there is technology spillover 
in the Indian pharmaceutical industry. TRIPS implementation has insignificant effects on 
R&D innovation. It is also found that exporting firms and firms with a higher productivity 
level are significantly more likely to carry out R&D activities.   
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1. Introduction: 
It is said that, globalization will lead to dumping which could adversely affect the 
production and employment in other countries. The Indian pharmaceutical industry (IPI) has 
already been affected in to its business by none other than neighboring China. For instance, due 
to dumping, some bulk drugs producing units stopped manufacturing drugs in Andhra Pradesh, 
Gujarat and Karnataka (Lalitha, 2002). It is estimated that the Indian bulk drugs industry is 
losing its business amounting to Rs 2,500 crore a year due to cheap bulk drugs imports from 
China (Chaudhuri, 2011). The major problem for India is too much dependence on China for the 
import of bulk drugs. Regarding the Chinese bulk drugs production that China excelling over 
India, Indian Drug Manufacturers’ Association (IDMA) President, S.V. Veeramani said that it is 
due to subsidies provided to the industry by the Chinese government. India is also planning to 
extend similar support to pharmaceutical industry, such as more funding, subsidies, quicker 
environmental clearances, etc.
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But the comparative advantages of these two countries are different. China’s comparative 
advantage is in the low value end i.e. bulk drugs, and India’s comparative advantage is in the 
high value end .i.e. generic drugs. According to Edelweiss report of Nov 2014, India has some 
700 US-FDA approved facilities, and China has about 600 such US-FDA approved plants. 
However, India got approvals for more than 300 drug master files (DMFs) accounting for nearly 
a third in the US market, whereas China lagged with around 150 DMFs approved. So, Chinese 
pharmaceutical firms aim to move up in higher value chain in the Life Sciences sector by 
investing huge amount of money and scouting across the globe for talents. For example, Chinese 
drug firms hired senior Indian scientists to gain competence in the formulations segment by 
paying higher salaries. Confirming the trend, Director General of India's Pharmaceuticals Export 
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 “Drug sector needs boost to reduce dependency on China: IDMA” Economic Times, Sep 2, 2015. 
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/drug-sector-needs-boost-to-
reduce-dependency-on-china-idma/articleshow/48775030.cms 
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Promotion Council (Pharmexcil), P.V. Appaji told the Economic Times that "Several instances 
of certain leading Chinese pharmaceutical firms hiring top Indian pharmaceutical scientists 
have come to our notice. It could be aimed at augmenting filing of abbreviated new drug 
applications (ANDAS) in the US and other regulated markets as China is currently building huge 
capacities to produce copycat medicines. We guess this trend should over a period of time help 
Indian companies increase their presence in China and vice versa” (Economic Times, 1st Sep, 
2015). This strategic move can enable Chinese pharmaceutical firms to increase filings of 
ANDAS in the US and other regulated markets. This trend is happening at a time when India is 
trying to reduce its imports of raw materials from China. Chinese firms have increased 
significantly their R&D investments over the years. It increased from $162 million in 2000 to 
$3,250 million in 2011.  
The IPI consists of both small and large firms. Small pharmaceutical firms are lacking in 
investments, skills and technologies. They are now restricted from accessing technical 
innovation that comes from reverse engineering.  Since these firms mainly produce bulk drugs, 
rising imports of bulk drugs adversely affect them. Many foreign MNCs who had left during the 
1970s are coming back to India. This return will gradually erode India’s cost advantages as it 
leads to increase in drugs prices and imports of high priced finished formulations (Chaudhuri, 
2011).  While China moves up the value chains from manufacturing ‘simple to manufacture’ 
molecules to ‘more complex to manufacture’, many domestic companies are setting up their labs 
abroad due to lack of expertise in India in the areas necessary; and shifting their R&D activities 
to the western countries where there is plenty of trained personnel and good infrastructure which 
is lacking in India; to boost margins by producing high-value drugs due to regulatory morass at 
home, such as lacking of concrete regulations for clinical trials.  
It is true that Indian domestic pharmaceuticals companies become more competitive, and 
enable to move up to higher value chains. For instance, Nicholas Piramal is talking with Chisei 
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Pharmacy to bring in ‘curosur’ a biotech drug that can be used for the survival of premature 
babies. It is also entering into co-licensing and marketing deal with Roche Pharmaceuticals of 
the US to introduce a biotech cancer drug ‘peg interferon’2. Another pharma major Ranbaxy had 
obtained exclusive marketing rights from a US firm to sell a cardiovascular drug in several Asian 
countries including China, South Africa and with non-exclusive rights in Mexico (Lalitha, 2002). 
Indian exports market share has increased from 65.2% in 1993 to 81.2% in 2013. R&D 
expenditures have increased from 3.88% growth rate in Pre-TRIPS period to 5.07% growth rate 
in the Post-TRIPS (Kiran, and Mishra, 2009b).  The total R&D expenditures significantly 
increased from 2005 onwards, i.e. from $40.82 million in 1999 to $326.15 million in 2005 to 
$1,134.16 million in 2014 (Table 1).  Both domestic and foreign R&D expenditures have 
increased significantly in absolute terms. However, in terms of percentage share, domestic R&D 
expenditures shares have occupy major shares of the total. The percentage share of R&D 
expenditures incurred by domestic firms has increased from 62.03% in 1999 to 71.59% in 2005 
and to 84.27% in 2014. Foreign R&D expenditures consistently decrease from 2006 onwards. 
R&D expenditures incurred by foreign companies have decreased from 37.97% in 1999 to 28.41% 
in 2005 and to 17.22% in 2014. It indicates that after the full implementation of product patent, 
pharmaceutical companies have started investing huge amount in R&D activities and domestic 
companies take the lead. 
By 2014, out of the top ten companies that had invested substantially in R&D activities, 
eights are Indian domestic companies (Table 2). Ranbaxy Laboratories Ltd. and Mylan 
Laboratories Ltd are the only two foreign companies included in the list. These eight companies’ 
shares accounted for more than 57% of the total R&D expenditures in 2014. The first top 
pharmaceutical companies in term of R&D expenditure percentage share in 2014 are Dr. Reddy's 
                                                          
2
 ‘Nicholas in Talks for Biotech Deals’ The Times of India, March 13, 2002, 
http://timesofindia.indiatimes.com/business/india-business/Nicholas-in-talks-for-biotech-
deals/articleshow/3602401.cms? 
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Laboratories Ltd. (15.02%), Lupin Ltd. (13.43%) and Cipla Ltd.(7.39%). It indicates that 
domestic pharmaceutical companies have significantly increased their R&D expenditures 
whereas foreign companies have incurred less R&D expenditures. By 2005, offshore outsourcing 
to domestic firms started to include highly advanced R&D activities. Patent activities and patent 
filings such as Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAS) 
with US-FDA by Indian pharmaceutical firms have significantly increased. The proportion of 
DMF filings by India has increased more than three times in the last few years. ANDA approvals 
held by Indian firms as a percentage of total approvals went up sharply from 17% in 2001 to 43% 
in the first quarter of 2013 (Chaudhuri, 2007). Out of 4,000 pending applications at the United 
States Food and Drug Administration (US FDA), Indian firms had filed 1000 applications and 
are waiting for clearance. The approval number is expected to cross 500 if the US FDA does not 
ask additional details such as complete response letter. Among the highest US FDA approval 
Indian companies, in 2015, Lupin got 19 products approval and is followed by Aurobindo with 
17 FDA approvals in the same year. Some of new companies through these products will enable 
to enter into new market that has so far seen limited competition, indicating a cut in profit 
margins. This faster US FDA nods will accelerate sales growth of Indian pharmaceutical 
companies. 
Due to the lack of capital, many of the domestic firms go for merger and acquisitions 
(M&A) and consolidate their business by acquiring the manufacturing facilities or brands of 
other firms. For instance, Indian domestic companies such as Dr. Reddy’s, Aurobindo, Cadila 
Healthcare, Torrent, have signed supply agreements with MNCs such as GSK, Astrazeneca and 
Abbot. Accordingly, Dr. Reddy’s will supply about 100 branded formulations to GSK in 
different emerging markets such as Latin America, Africa, Middle-East and Asia-Pacific 
(excluding India). Likewise, Aurobindo will supply more than 100 formulations to Pfizer for the 
regulated markets of the US and the EU countries, and more than 50 products for about 70 non-
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US/EU markets. Besides revenues sharing, Pfizer pays upfront license fees to Aurobindo (Dinar, 
2005).  Sun Pharmaceutical Industries Ltd has the highest M&A undertaken, having 8 mergers 
including Ranbaxy Laboratories. It is followed by Piramal Enterprises Ltd, having 7 mergers so 
far. Similar trends have also been seen in other developing countries, like Argentina, Brazil and 
Mexico after the regulatory policies change (Jha, 2007). The advantage of this is that many 
MNCs can produce drugs at lower cost as well as saving time and money and can sell drugs in 
both emerging and regulated markets.  
Table 1: R&D expenditures of the Indian pharmaceutical Industry: 1999-2014 (in 
US$ million and in percent) 
Year Total R&D (in 
$million) 
Domestic R&D (in 
$million) 
Foreign R&D (in 
$million) 
Domestic R&D 
(%change) 
Foreign R&D 
(%change) 
1999          40.82          25.32          15.50          62.03          37.97  
2000          58.27          39.80          18.47          68.30          31.70  
2001          71.60          54.17          17.43          75.66          24.34  
2002          96.35          76.53          19.82          79.43          20.57  
2003       134.37          91.68          42.69          68.23          31.77  
2004       226.69        160.94          65.75          71.00          29.00  
2005       326.15        233.48          92.67          71.59          28.41  
2006       423.11        293.98        129.13          69.48          30.52  
2007       547.22        422.65        124.57          77.24          22.76  
2008       641.49        489.45        152.04          76.30          23.70  
2009       613.83        474.66        139.17          77.33          22.67  
2010       799.16        622.72        176.44          77.92          22.08  
2011       959.84        773.66        186.18          80.60          19.40  
2012       959.96        794.67        165.29          82.78          17.22  
2013    1,045.23        869.25        175.98          83.16          16.84  
2014    1,134.61        956.17        178.44          84.27          15.73  
Source: Prowess database, CMIE 
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Table 2: Top 10 R&D Expenditure Incurred Pharmaceutical Companies in 2014 (in US$ million) 
Sl. 
No. 
Companies 2005 2010 2011 2012 2013 2014 
1 Dr. Reddy'S Laboratories Ltd. 57.64 88.29 121.29 123.62 127.69 170.31 
2 Lupin Ltd. 17.4 78.47 107.45 103.89 130.48 152.33 
3 Ranbaxy Laboratories Ltd. 
[Merged] 
75.35 101.26 105.86 86 82.17 86.52 
4 Cipla Ltd. 20.42 55.1 57.74 60.89 66.87 83.9 
5 Cadila Healthcare Ltd. 16.25 38.75 56.52 71.22 81.37 71.43 
6 Mylan Laboratories Ltd. 3.65 51.2 56.32 55.08 69.74 69.12 
7 Sun Pharmaceutical Inds. Ltd. 16.98 31.67 34.96 36.4 50.09 61.5 
8 Aurobindo Pharma Ltd. 8.22 21.38 30.99 31.66 38.33 41.8 
9 Piramal Enterprises Ltd. 11.34 7.95 9.55 36.62 43.58 39.35 
10 Wockhardt Ltd. 11.53 8.77 7.4 8.88 36.94 32.53 
Source: Prowess database, CMIE 
All these lead to the increase in the market shares of the MNCs in the domestic 
formulations market, increased from less than 20% in March 2008 to 28% in December 2010 
with the taking over of Ranbaxy by Daiichi Sankyo in June 2008; Dabur Pharma by Fresenius 
Kabi Oncology in August 2008; ShanthaBiotechs by Sanofi-Aventis in July 2009 and the 
domestic formulations business of Piramal Healthcare by Abbott in May 2010. Among the top 
10 pharmaceutical companies in India, the number of MNCs has increased from one (i.e. GSK) 
in March 2008 to three (i.e. GSK, Ranbaxy and the Abbott group) in December 2010. The 
Abbott group, which was the 30th largest company with a market share of only 1.1% in March 
2008, (comprising Abbott, Piramal Healthcare and Solvay Pharma) now, becomes the largest 
company in India occupying 6.2% market share followed by the Cipla (5.7%). If the MNCs have 
taken over some remaining major Indian companies such as Cipla (5.7% market share in 2010), 
Sun (4.3%), Cadila Healthcare (3.9%), Mankind (3.2%), Alkem (3%), Lupin (2.9%), their share 
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will exceed 50% immediately paving way to dominate the IPI. With the abolition of the Foreign 
Exchange Regulation Act (FERA), the MNCs listed in Indian stock exchanges have increased 
their equity stakes accounting for more than 50%. For instance, Novartis has increased foreign 
equity from 50.93% in 2005 to 76.42% in 201, Pfizer from 40% to 70.75%, Abbott from 61.7% 
to 68.94% and Aventis from 50.1% to 60.4% (Chaudhuri, 2011). This is not welcoming news for 
the domestic firms.  
Since product differentiation is impossible in the pharmaceuticals industry, increasing 
productivity and innovation becomes very important for the survival of Indian pharmaceutical 
firms. This prompts domestic firms to increase their R&D investments. It is quite important to 
examine the effects of foreign ownership and IPR protection on the innovation in the IPI. The 
study investigates it by using the firm-level panel data. We find that there is a positive and highly 
significant level of foreign ownership effect on R&D activity and TRIPS implementation has 
insignificant effects on R&D innovation. This paper is arranged as follows. Section II gives the 
literature review. Section III shows data and empirical specification. Finally, Section IV 
summarizes the results and concludes. 
 
2. LITERATURE REVIEWS: 
Theoretical analysis suggests that there are two major arguments for and against of 
tighter IPRs. One argument suggests that tighter IPRs encourage innovation thereby benefitting 
all regions, though many countries especially developing countries cannot totally agree with it. 
Another argument goes against the tighter IPRs as they only strengthen the monopoly powers of 
large companies of developed countries, to the detriment of the developing countries. A patent 
provides protection to a patentee from imitators and a country with relatively higher productivity 
level innovates more and can easily adopt new technology (Eaton & Kortum, 1996). Kim et al., 
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(2012) also suggested that patent protection stimulates innovation and contributes in economic 
development only in developed countries. Implementation of patent only stimulates innovation in 
those countries with high level of development, education and economic freedom (Qian, 2007; 
Sweet & Maggio, 2015). Lai & Qiu (2003) examined the effects of strong IPRs protection in 
developing countries. They found that developing countries will benefit from the implementation 
of IPRs if they can implement the same IPRs standard of the developed countries. Stronger IPRs 
benefitted developing countries through technology transfer, increase in R&D activities, etc. 
(Dinopoulos et al., 2010) and by increasing royalty payments for technology transfers to 
affiliates, R&D expenditures, and foreign patent filings (Branstetter et al., 2006; Vita 2013). 
Branstetter et al. (2011) found that MNEs expanded their industry activities and accelerated 
transfer of technology to the South after IPRs reforms. They concluded that the activities of 
MNCs were expanded and it compensated the decrease in imitative activity in the South after the 
reform. Though there is temporary increase in innovation, the developing countries lose from 
tighter IPRs  (Helpman, 1993).   
Knowledge spillovers and their relation to the economic growth are empirically well 
established by Griliches (1979, 1992). Griliches (1986) examined the importance of R&D in 
enhancing productivity growth in U.S. manufacturing and found that R&D increased 
productivity growth. Analyzing the existence and magnitude of R&D spillovers, Griliches (1992) 
confirmed that R&D spillovers are both prevalent and significant. Coe and Helpman, (1995) 
estimated the FDI spillovers through R&D stocks. They found that returns on R&D activity were 
high in both output and international spillovers. Thus, a country’s productivity level depends on 
R&D stocks. R&D enhances its productivity level (Griliches, 1986) through benefits from 
foreign technical advances and effective use of existing resources. Privately financed R&D 
expenditures were more significant than that of state financed R&D expenditures.  Successful 
innovation required efficient assimilation of new knowledge and ideas in its innovation process 
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and such knowledge partly were got from foreign countries (Cassiman and Veugelers, 2002).  
Coe and Helpman (1995) argued that foreign R&D stimulated domestic productivity more to 
those economies which were more open to foreign trade and to those firms which were engaged 
more in their own R&D. Confirming this finding, Aw, Robert et al. (2007) found that exports 
and R&D were complementary for productivity growth, with R&D activities facilitating its 
ability to benefit from exposure to the export market.  
Case studies suggest mixed evidence on the technology spillover to domestic firms. 
Aitken and Harrison (1999) found that there were no knowledge spillovers to domestic owned 
firms using the panel data on Venezuela firms. However, every OECD country other than the US 
benefited from foreign ideas in achieving higher its productivity growth (Eaton & Kortum, 1996). 
Girma et al., 2008 examined the two-way relationship between R&D and export activity using 
firm-level databases for the Republic of Ireland and Great Britain. They found that exporting 
experience increased the innovative capability of Irish firms through increasing R&D activity 
and no strong learning-by-exporting effects for British firms.  
To examine whether stronger IPRs and implementation of TRIPS stimulate innovation 
for the pharmaceutical industry in the developing economies, Croix and Kawuara (1996) 
examined the effect of the adoption of product patents for the Korean chemical and 
pharmaceutical industry and found that the adoption of stronger patent laws decreased Korea’s 
wealth. The implementation of TRIPS had increased the patenting activities and R&D 
investments of the domestic pharmaceutical companies (Chaudhuri, 2007; Chadha, 2009; Bedi et 
al., 2013) and increased sales and export performances of the companies (Kiran & Mishra, 
2009a). This finding is in line with that of Guennif & Ramani (2012) that the IPI has had more 
success in industrial capabilities than that of Brazil due to State policy after the IPRs reform. 
McCalman (2001) empirically analyzed the impact of international patent harmonization as 
implied by the TRIPS agreement. He found that most of the developed countries benefitted and 
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developing countries including India suffered a net loss from raising IPRs protection. However, 
as far as Indian consumer welfare is concerned, Chaudhuri et al., (2006) found that though the 
implementation of TRIPS resulted to some welfare loss, the TRIPS would not have much 
detrimental effect on the IPI, as it increased domestic firms’ profits. Allred and Park (2007) 
examined the relationship between patent strength, firm innovation and innovation diffusion 
using country and firm level data. They found that patent strength reduced domestic patent 
filings and had insignificant effects on R&D and foreign patent filings for developing countries. 
For developed countries, it increased R&D and domestic patent filings, and reduced foreign 
patent filings.  Niosi et al. (2012) for India and Jiatao (2003) for China confirmed that diffusion 
patterns, shaped by national policies, were critical as the process is uneven among developing 
countries. They identified  large human capital pools, strong institutions in the national 
innovation system, large established firms, industrial structures, and institutional factors such as 
science, technology, linkages with universities, as well as public research and market size as key 
success factors for knowledge accumulation (Jiatao, 2003) or for diffusion in developing 
countries (Niosi et al.,2012). Ala (2013) also found the negative effects of TRIPS 
implementation on innovation in case of Bangladeshi pharmaceutical firms. The implementation 
of TRIPS did not improve R&D capabilities in Bangladesh and reduced competitiveness in 
LDCs (Ala, 2013). 
Pradhan (2003) empirically examined the impact of trade liberalization on R&D 
investments of the IPI and found that changes in regulatory environment had forced domestic 
firms to increase their R&D activities in order to develop better products. Feinberg et al. (2001) 
also empirically examined whether knowledge spillovers from MNCs’ local R&D benefits 
domestic firms and found that the industry experienced technology spillovers from foreign FDI, 
but R&D spillovers only took place among MNCs themselves. There is no technology spillover 
from MNCs to domestic firms. Saranga & Phani (2009) examined the role of operational 
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efficiencies in the survival and growth of Indian domestic firms as a result of changes in 
regulatory regime in the IPI. They found that the domestic (older) firms were more efficient than 
the MNCs (younger firms) and increased R&D investments is associated with increased 
operational efficiencies. Iyer (2012) also found that there was no R&D spillover effect from both 
foreign and domestic MNCs on domestic firms. Foreign firms didn’t significantly affect 
domestic firms’ productivities.  
 
3. DATA  
The paper uses annual census data of over 552 pharmaceutical firms, allowing us to 
measure the productivity effects of foreign ownership. We obtained our data from the Center for 
Monitoring Indian Economy’s (CMIE) Prowess Database. This database has been used in many 
empirical studies for Indian economy such as Pradhan (2002), Saranga & Phani (2009), Iyer 
(2012), etc. The study covers the period from 1999 to 2014. The share of foreign equity 
participation for a firm in time ‘t’ is a proxy for foreign ownership. Its value ranges between 0 to 
100 percent. Since most of the companies in the CMIE database don’t fully disclose their 
employment number, we use labor input from the Annual Survey of Industries (ASI) data. It is 
calculated by dividing total wage bill of a firm by the average industry wage rate. However, 
since the ASI has not provided wage rates for the last two years, labor inputs for these particular 
years have been obtained from Prowess database. Capital, size, exports and raw materials of the 
firm in time ‘t’ are taken from the CMIE’s Prowess Database. TRIPS compliance data comes 
from Kyle and Mcgahan (2008). 
3.1. Specification 
There are three major hypotheses regarding the major determinants of R&D investment. 
The patent rights protection hypothesis, which indicates that the rate of R&D investment is 
13 
 
positively correlated with the stronger IPRs protection. The second is the international 
technology transfer hypothesis, which claims that foreign R&D activities’ benefits can be 
transmitted through trade and FDI and affect domestic R&D investment decisions. The third is 
the income growth hypothesis, which states that the R&D intensity is closely related to income 
changes (Wang, 2010).  
Our focus is to analyze the evidence on the relations between foreign ownership, IPR 
protection and innovation. The role of technology in firm’s productivity growth becomes a very 
important issue in the IPI, since innovation is the key factors that the Indian pharmaceuticals 
firms could stay competitive in the global market. There are ample of empirical studies that 
confirm that there is a positive role for R&D expenditure in explaining firm’s productivity 
growth (see Griliches and Mairesse, 1990; Nadiri, 1993; Wakelin, 2001). We also try to examine 
whether the foreign ownership improves their technology through innovation and thereby 
increasing productivity. In other words, whether there are important technological spillovers in 
the IPI and how they affect the productivity growth of domestic firms. 
The specification of the estimate is given by: 
𝐿𝑜𝑔𝑖𝑡 (𝑅&𝐷𝑖𝑡 = 1) = 𝑓(𝑙𝑎𝑔𝑔𝑒𝑑 𝑜𝑤𝑛𝑒𝑟𝑠ℎ𝑖𝑝, 𝑙𝑎𝑔𝑔𝑒𝑑 𝑒𝑥𝑝𝑜𝑟𝑡, 𝑙𝑎𝑔𝑔𝑒𝑑 𝑇𝐹𝑃, 
                                                                         𝑙𝑎𝑔𝑔𝑒𝑑 𝑇𝑅𝐼𝑃𝑆, 𝑙𝑎𝑔𝑔𝑒𝑑 𝑓𝑖𝑟𝑚 𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒𝑠)  (1) 
R&D is a dummy equal to one if it has any positive R&D expenditure in time,‘t’ and zero 
otherwise (i = 552 companies, t = 1999-2014). Foreign ownership (indicated by ownership) is 
the share of foreign equity participation at the firm level in the previous year, which varies 
between 0 and 100 percent. If foreign ownership in a firm increases that firm’s productivity, the 
coefficient of ownership will be positive. Export is a dummy, 1 indicates a firm exports in time, 
‘t-1’ and 0 otherwise. It is expected that exports should have positive coefficient if exports 
increase firm’s productivity. Lagged TFP indicates a firm’s productivity in the previous year. We 
estimate TFP using Levinsohn-Petrin (LP) semi-parametric. Size represents market size and 
14 
 
capabilities of a firm. The coefficient of TFP is expected to be positive sign, as higher 
productivity firms will invest more on R&D activities. TRIPS is a dummy, 1 indicates that the 
years after which India fully implement ‘product patent’ in 2005, and 0 indicates the year before 
2005. We expect the coefficient of TRIPS will be positive on R&D activities since undertaking 
R&D activities are necessary to fight tough competition with many foreign competitive firms for 
their survival. By protecting IPRs, TRIPS allows technology transfer and diffusion, and relates to 
a set of administrative and market-organizing regulated rules. They enable agents to use or 
transfer resources among each other, and allow governments to achieve economic efficiency 
which is one goal observed in IPRs regulations, or product liability and safety regulations. The 
firm attributes include firm size and it is a control variable. We expect a positive sign of its 
coefficient as firm size represents market power and capabilities. Large firms have higher market 
access and higher capabilities than small firms. It is expected that size will increase productivity 
growth of firms. 
3.2. Empirical Results 
Table 3 gives the different estimated results of equation (1). In column (1) and (2), it is 
calculated by using the logit model. Column (2) differs from column (1) in that lagged size is 
added in column (2). In column (1) and (2), the coefficients of foreign ownership are positive 
and highly significant at 1 percent level, which are 0.035 and 0.026 respectively. The coefficients 
of export dummy are positive and highly significant. The coefficient of TFP is also positive and 
significant (p=0.000) in column (1) and is positive and insignificant in column (2). The 
coefficient of TRIPS, in both columns, is negative and insignificant. The coefficient of size, in 
column (2), is also positive and significant (p=0.000). However, these estimated coefficients are 
likely to be biased due to ignoring unobserved heterogeneity. 
To check biasness, we re-estimate the equation (1) using logit fixed effects model in 
column (3) and (4). We run Hausman test and the result indicates rejection of the null hypothesis 
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of uncorrelated time-invariant unobserved heterogeneity with the regressors, only fixed effect is 
consistent. In column (3), the coefficient of ownership is positive and significant at 5 percent 
level. It indicates that foreign-owned firms are more likely to undertake R&D activities. It also 
suggests that there is international technology spillover in India. Some of the possible reasons are 
discussed herewith. Since foreign MNCs have been losing their market shares and profits, due to 
drop of sales and expiry of patent for blockbuster drugs, rising costs and declining R&D 
revenues, they found India a profitable place to reallocate their R&D activities in India because, 
India is becoming a global hub of offshore outsourcing for R&D activities. Besides, India has the 
largest number of US-FDA approved facilities outside the United States with large pool of cheap 
and skilled manpower. Thus, foreign firms invest and relocate their R&D activities in India. 
They want to discover more new products. Once a new drug has been developed, its marginal 
cost of production becomes lower. Formula of the drugs needs not to be improved. The same 
formula can be applied to produce at different locations. Given India’s comparative advantages, 
foreign MNCs invest in R&D in order to get monopoly rents from new varieties of drugs. 
As far as domestic pharmaceutical firms are concerned, most of them produce generic 
drugs. The quality of such drugs must be high. In order to produce such high quality products, 
firms should be more innovative. Domestic pharmaceutical firms are more focused on 
developing innovations for regulated markets, particularly for the US markets. They must invest 
more on R&D activities to increase their productivity levels. Patents activities and filings by 
domestic companies registered the highest increase during the study period. Pharmaceutical 
products are knowledge-based products. These products are non-excludable (Grossman and 
Helpman, 1991). It implies that the patentees of new product might not get full compensation 
from all the agents that make use of it. They only get benefits from the patents on their new 
products.  
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Table 3: Impact of foreign ownership and IPR Protection on the Innovation of firms in the Indian 
Pharmaceutical Industry: 
     R&D Dummy 
Logit   Fixed Effects     
   (1)     (2)     (3)    (4)                   
Lagged Ownership    0.035  0.026  0.048  0.038   
   (0.005)*** (0.005)***   (0.023)** (0.024)         
Lagged Export  2.405  2.214  1.497  1.498   
    (0.180)*** (0.186)***    (0.421)*** (0.426)***     
Lagged TPF  0.000  0.000  0.000  0.000    
   (2.01e-07)***  (3.01e-07)   (6.03e-07)**  (9.07e-07)  
Lagged TRIPS  -0.041  -0.078  -1.712  -1.922   
   (0.541)  (0.559)  (1.116)  (1.187)          
Lagged Size    0.000    0.000     
               (2.61e-09)***   (1.15e-08)*   
Year fixed effects      YES  YES  YES  YES    
Constant  -2.255  -2.093      
   (0.266)*** (0.272)***     
N   1717  1676  468  448    
Log likelihood  -808.39  -756.93  -169.95  -159.24        
Prob>Chi2  0.0000  0.0000  0.0003  0.000   
LR Chi2(15)        LR Chi2(16)        LR Chi2(15)    LR Chi2(16)     
             = 742.19  =779.54  =40.96         =48.21              
Pseudo R2  0.3146  0.3399  
NOTES: Robust standard errors are in parenthesis. *** indicates significance at 1% level, ** at 5% level 
and * at 10%. Standard errors in parentheses. 
 
The export coefficient is highly positive and significant, which is 1.497. It suggests that 
exporting firms are more likely to invest in R&D. It is consistent with Girma et al., 2008. They 
found that previous year exporting activities increase the innovative capacities of Irish firms 
through increase in R&D activity. In other words, Indian pharmaceutical firms increase its 
probability to undertake R&D activities when they enter into export markets. After entering into 
export markets, firms face a tough competition from many MNCs. They must learn to get new 
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skills and knowledge in order to be more competitive so that they can produce niche products. It 
necessitates domestic firms improving their product qualities, designs, production processes so 
that they can meet the demands of domestic and foreign markets. For such a task, their 
managerial and operational efficiencies must increase and undertaking exports activities help 
them achieved such efficiencies through interaction and collaboration with foreign agents. These 
activities lead to increase in firm’s innovative capabilities. Such kind of export competitiveness 
is only possible when firms invest huge amount in R&D activities (Pradhan, 2002), as 
investments in innovation are required to increase firm’s capabilities. 
The coefficient of TFP is positive and significant. But its coefficient is very minimal. It 
indicates that firms with a higher productivity level are more likely to perform R&D activities. 
Thus, productivity plays an important role in undertaking innovative activities. Productive firms 
are generally large in size and have more financial flexibilities. They can invest a large amount 
of money for innovative activities, thereby enhancing their innovative capabilities. Surprisingly, 
the coefficient of TRIPS is negative but insignificant. It is quite opposite to our expectation. 
Allred and Park (2007) also found similar results. They found that patent protection 
insignificantly affect R&D activities in developing economies. The negative coefficient suggests 
that TRIPS implementation does not encourage R&D activities. 
In column (4), firm attributes i.e. lagged size is added to the baseline model. The 
coefficient of ownership becomes positive but insignificant. The export coefficient have similar 
pattern, positive and significant. However, the TFP coefficient becomes positive and 
insignificant. The effect of TRIPS is still negative and insignificant. The coefficient of firms’ 
size is positive and significant. Its effect is very small. It suggests that there is a positive 
relationship between firm size and innovation, indicating that larger firms have higher possibility 
to undertake R&D activities. Large firms have higher market access and can appropriate 
economic rent from innovative activities. Since R&D undertaking requires a large amount of 
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investment and also involves risks, large firms can undertake such kind of activities, given their 
resource base and economies of scale. Thus, larger the firm size higher its probability to do R&D 
activities.   
Table 4: Impact of foreign ownership and IPR Protection on the Innovation of firms in the Indian 
Pharmaceutical Industry: 
   R&D Dummy 
   Random Effects  
     (1)  (2)  
Lagged Ownership     0.073  0.054  
    (0.017)*** (0.018)*** 
Lagged Export  2.843  2.623  
     (0.452)*** (0.451)***  
Lagged TPF  0.000  0.000   
   (5.86e-07)*** (8.25e-07) 
Lagged TRIPS   -1.652  -2.018  
   (0.969)*  (1.013)** 
Lagged Size     0.000   
     (8.10e-09)***  
Year fixed effects      YES  YES   
Constant  -2.993  3.026  
   (0.595)***    (0.607)***  
N   1717  1676   
Log likelihood  -445.19  -417.48 
Prob>Chi2  0.0000  0.0000  
WALD Chi2(15)   WALD Chi2(17) 
   =111.71 =108.13  
NOTES: Robust standard errors are in parenthesis. *** indicates significance at 1% level, ** at 5% level 
and * at 10%. Standard errors in parentheses. 
 
For robustness checking, we re-estimate the equation (1) using random logit model. Table 
4 gives the results. In column (2) firm’s size is added. The results are consistent with different 
methods. The coefficients of ownership and export are all positive and significant in both 
columns. The coefficient of TFP is positive and significant in column (1) but positive and 
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insignificant in column (2) when firm size is added. The only different is the coefficient of 
TRIPS. The coefficient of TRIPS, in both column, is negative but significant (p=0.088; p=0.46). 
It suggests that trade liberalization and TRIPS implementation don’t go in favor of increasing 
R&D activities in the IPI. One of the possible reasons is that patent systems restrict imitation and 
copycat of patented technologies (Alfred & Park, 2007).It also increases transaction costs for 
technological exchange. Stronger patent protections increase the cost of technological inputs. 
This reduced technology transfers among countries. Due to stricter patent protection, local agents 
must pay for access to technological inputs and knowledge that used to be free. Since most of the 
Indian pharmaceutical firms are small firms, only large firms can undertake R&D activities. It 
implies that the small firms could not undertake R&D activities due to financial and resource 
constraints. These reduce the chances of local agents to increase innovative capabilities through 
imitation or learning by doing, reducing innovation.  
Patent holders are suspicious of domestic pharmaceutical companies doing reverse-
engineering and imitation of their patented drugs. They try to restrict them from accessing their 
technologies. Stronger patents protection may not provide the incentives to patent holders to 
upgrade or develop new technologies if they face less competition. Increased market power 
increases monopoly power of foreign MNCs and they exploit more opportunities from existing 
technologies. They gain economic rents longer with fewer introductions of new technologies, 
leading to a slower rate of innovation activities. As far as the benefits from the TRIPS agreement 
are concerned, McCalman (2001) also found that stronger patent protection resulted in 
significant loss to India. Unless patent reforms have a significant impact on developing-country’s 
R&D, they could have largely negative impacts on domestic patenting. As expected the firm’s 
size is positive and significant. 
 
4. Conclusions 
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The literature on the R&D spillovers suggests that the role of R&D spillover effects is 
mixed in the case of developing countries. Product innovation mainly depends on R&D 
resources and the costs of R&D (Grossman & Helpman, 1990b). We have presented an overview 
of the preferences that MNCs in locating their R&D activities in India. It is cost considerations 
and the availability of a vast pool of human resources that brings MNCs to India. Our main 
concern was to investigate the impacts of R&D and IPR protection on the innovation in the IPI. 
What emerges is foreign firms encourage domestic pharmaceutical firms to undertake R&D 
activities and increase their innovative activities. It will in turn make the industry more 
competitive in the long run through this technology spillover. This technology spillover might be 
due to India’s comparative advantage. Besides, foreign MNCs have lost its market share and 
profits, due to drop of sales and expiry of patent for blockbuster drugs, rising costs and declining 
R&D revenue. 
Foreign MNCs might come and invest in R&D activities in order to get monopoly rents 
from new varieties of drugs. Since most of domestic pharmaceutical companies produce generic 
drugs, the quality of such drugs must be high to meet demand from domestic and foreign 
consumers. In order to produce such high quality products, domestic firms should be more 
innovative. They must invest more on R&D activities to increase their productivity levels. All 
these factors compel them to enter R&D agreement with leading domestic firms. The 
government incentive such as tax benefits, grants and soft loans for promoting R&D may 
contribute in attracting more R&D activities. TRIPS may have provided incentives and 
confidence to MNCs to take advantage of country’s strength in manufacturing and to look for 
location for R&D in India. It indicates that firms incur more R&D expenditure inducing high 
innovative activity and more patents by domestic firms in India. It prompts that most of the 
developing countries introduce patent protection for new drug products and lead to do more 
research on innovation.  
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Exporting firms are more likely to invest in R&D activities. Since pharmaceutical is a 
knowledge-intensive industry, entry into export markets depends on firm-specific knowledge 
like better qualities, innovative design and marketing. Otherwise they cannot compete with the 
global peers. Such kind of export competitiveness is only possible when firms invest huge 
amount in R&D activities. Regarding TFP, firms with a higher productivity level are 
significantly more likely to do R&D activities. However, the coefficient of TRIPS is negative 
and insignificant. But it is negative and significant when we estimate it using random effects 
model. It is quite interesting that trade liberalization and TRIPS implementation don’t stimulate 
R&D activities in the IPI. It is against our expectation. It suggests that trade liberalization and 
TRIPS implementation don’t go in favor of increasing R&D activities at least for this industry. 
The outcome may be due to increasing monopoly powers of foreign MNCs, increasing 
transaction costs and restriction of imitation and reverse-engineering of foreign technologies as a 
result of TRIPS implementation. As expected, the firm’s size is positive and significant. It 
implies that large firms have higher market access and can appropriate economic rent from 
innovative activities, for R&D undertaking requires a large amount of investment and also 
involves risks. Large firms can undertake such kind of activity, given their resource base and 
economies of scale. Thus, larger the firm size higher its probability to do R&D activity.  
It is recommended to add more variables such as location, FDI, etc. Whether location and 
FDI play significant role in technology spillovers will be an interesting issue. Other variables 
like compulsory licensing and parallel imports may have impact on pharmaceutical exports and 
innovation. Such variables can be included in future study. Since our analysis is based on only 
one industry i.e. pharmaceutical industry, it is highly recommended to examine the effect of 
foreign ownership on more disaggregated data. 
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